<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676828</url>
  </required_header>
  <id_info>
    <org_study_id>KFE-1930</org_study_id>
    <nct_id>NCT04676828</nct_id>
  </id_info>
  <brief_title>Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer</brief_title>
  <acronym>ASPECT</acronym>
  <official_title>Functional Lung Avoidance SPECT-guided (ASPECT) Radiation Therapy for Lung Cancer Patients: Phase II Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Westmead and Blacktown Hospital, Sydney West Radiation Oncology Network, Sydney, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study aims to determine if functional lung avoidance based on perfusion single photon&#xD;
      emission (SPECT)/CT scan, improves toxicity outcomes for patients with advanced lung cancer&#xD;
      undergoing chemo-radiotherapy. Functional avoidance implies a dose plan that takes functional&#xD;
      distribution in the lung into account, and avoids highly functional lung volumes sparing them&#xD;
      from radiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this project, a novel method of safe radiotherapy delivery shall be tested for patients&#xD;
      with lung cancer in a clinical setting. Functional avoidance radiotherapy is a new method&#xD;
      that protect highly functional lung tissue from radiation, while delivering high dose&#xD;
      radiotherapy to the lung tumour. Radiotherapy is usually based on a CT scan that does not&#xD;
      account for functional variations in the lungs. Therefore, I hypothesize that using&#xD;
      functional distribution in the lungs and avoiding irradiation of highly functional lung will&#xD;
      improve treatment outcome for individual patients with lung cancer.&#xD;
&#xD;
      The objective of my project is to determine if functional image guided radiotherapy&#xD;
      (functional avoidance radiotherapy) improves toxicity outcomes for patients with lung cancer&#xD;
      undergoing curative chemo-radiotherapy in a prospective clinical trial.&#xD;
&#xD;
      To reach this objective, the impact of functional avoidance radiotherapy on pulmonary&#xD;
      toxicity measured by the incidence and severity of radiation-induced lung disease shall be&#xD;
      assessed. Additionally, loco-regional control, time to progression, overall survival, quality&#xD;
      of life and radiation-induced molecular response in patients treated with functional&#xD;
      avoidance radiotherapy shall be assessed and compared to patients receiving standard&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double-blinded phase 2</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Participants, care providers and outcome assessors are blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Radiation-induced lung toxicity</measure>
    <time_frame>Measured serially from 1 to 12 months after treatment completion</time_frame>
    <description>crude rate of symptomatic radiation-induced lung toxicity of grade 2 and higher. According to the Common Toxicity Criteria for Adverse Events version 5.0 for radiation pneumonitis, dyspnea, cough, or any other radiation-induced respiratory, thoracic and mediastinal disorder.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Measured serially from 1 to 12 months after treatment completion</time_frame>
    <description>Change in quality of life according to the European Organisation for Research and Treatment of Cancer quality of life questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported lung symptoms</measure>
    <time_frame>Measured serially from 1 to 12 months after treatment completion</time_frame>
    <description>Change in lung symptoms according to the European Organisation for Research and Treatment of Cancer questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at 12 months</time_frame>
    <description>time from randomization to disease progression at any site or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 12 months</time_frame>
    <description>time from randomization to death of any cause or last date known alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional control rate</measure>
    <time_frame>at 12 months</time_frame>
    <description>freedom from local disease progression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Radiation-Induced Disorder</condition>
  <condition>Radiation Pneumonitis</condition>
  <condition>Pulmonary Disease</condition>
  <condition>Lung Function Decreased</condition>
  <arm_group>
    <arm_group_label>SPECT functional avoidance treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SPECT-based radiation therapy given taken functional distribution in the lung into account, that avoids highly functional lung volumes sparing them from radiation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>CT-based radiation therapy given over 5- 6.5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Single-photon-emission CT scan</intervention_name>
    <description>SPECT/CT scan is an established functional modality used in the diagnosis and monitoring of lung disease. SPECT/CT scan images pulmonary circulation, where perfused areas equate with normal functional lung</description>
    <arm_group_label>SPECT functional avoidance treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically verified lung cancer (small-cell and non-small cell lung cancer)&#xD;
&#xD;
          -  referred for radiotherapy with curative intent&#xD;
&#xD;
          -  radiation dose of 60-66 Gy given in 2-Gy fractions, other dose levels and&#xD;
             fractionation schedules accepted, as per site standard&#xD;
&#xD;
          -  concurrent chemotherapy is accepted&#xD;
&#xD;
          -  patients with oligometastatic disease are allowed, where metastasis have been ablated&#xD;
             with surgery or radiotherapy&#xD;
&#xD;
          -  receiving (chemo)-radiotherapy to the thoracic disease with curative intent&#xD;
&#xD;
          -  adults over 18, that have given oral and written informed consent before patient&#xD;
             registration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  concurrent immunotherapy&#xD;
&#xD;
          -  previous radiotherapy to the thorax&#xD;
&#xD;
          -  other uncontrolled malignancies; any psychological, familial, sociological or&#xD;
             geographical condition potentially hampering compliance with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katherina Farr, MD PhD</last_name>
    <phone>+4550303580</phone>
    <email>katherina@oncology.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sydney West Radiation Oncology Network Westmead and Blacktown Hospitals</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Hau, MBBS PhD</last_name>
      <phone>0432207880</phone>
      <email>Eric.Hau@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Eric Hau, MBBS PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azza Khalil, MD, PhD</last_name>
      <phone>004578465000</phone>
      <email>azza.khalil@auh.rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Line Sparvath</last_name>
      <phone>004578465000</phone>
      <email>linspa@rm.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Katherina Farr, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Azza Khalil, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Katherina Farr, MD, PhD</investigator_full_name>
    <investigator_title>Specialist in Clinical Oncology</investigator_title>
  </responsible_party>
  <keyword>radiation-induced lung toxicity</keyword>
  <keyword>functional avoidance methodology</keyword>
  <keyword>radiation therapy of lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Radiation Pneumonitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

